GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Return-on-Tangible-Asset

Translate Bio (Translate Bio) Return-on-Tangible-Asset : 8.57% (As of Jun. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Translate Bio's annualized Net Income for the quarter that ended in Jun. 2021 was $68.6 Mil. Translate Bio's average total tangible assets for the quarter that ended in Jun. 2021 was $800.6 Mil. Therefore, Translate Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2021 was 8.57%.

The historical rank and industry rank for Translate Bio's Return-on-Tangible-Asset or its related term are showing as below:

TBIO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -89.97   Med: -58.23   Max: 5.7
Current: 5.7

During the past 5 years, Translate Bio's highest Return-on-Tangible-Asset was 5.70%. The lowest was -89.97%. And the median was -58.23%.

TBIO's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -40.005 vs TBIO: 5.70

Translate Bio Return-on-Tangible-Asset Historical Data

The historical data trend for Translate Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Return-on-Tangible-Asset Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Return-on-Tangible-Asset
-34.51 -89.97 -84.62 -58.23 -10.56

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.72 11.99 -10.31 13.42 8.57

Competitive Comparison of Translate Bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, Translate Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Translate Bio's Return-on-Tangible-Asset falls into.



Translate Bio Return-on-Tangible-Asset Calculation

Translate Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2020 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=-53.787/( (229.306+789.45)/ 2 )
=-53.787/509.378
=-10.56 %

Translate Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=68.576/( (792.175+809.004)/ 2 )
=68.576/800.5895
=8.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2021) net income data.


Translate Bio  (NAS:TBIO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Translate Bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Translate Bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109